Основная статистика
| CIK | 315545 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Provectus Biopharmaceuticals, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS B |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 18, 2025 |
2025 Annual Meeting of Stockholders presentation slides Exhibit 99.1 |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additiona |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36457 PROVECTUS BIOPHARMACEUTICALS, IN |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additiona |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additiona |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additiona |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employ |
|
| April 16, 2025 |
Letter from Marcum, dated April 16, 2025 Exhibit 16.1 |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS BIOPHARMACEUTICALS, |
|
| March 28, 2025 |
Exhibit 21 SUBSIDIARIES OF PROVECTUS BIOPHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation VisiRose, Inc.* Delaware Xantech Pharmaceuticals, Inc. Tennessee Pure-ific Corporation** Nevada Provectus Biotech, Inc. Tennessee Provectus Devicetech, Inc. Tennessee Provectus Imaging, Inc. Tennessee IP Tech, Inc. Tennessee Provectus Pharmatech, Inc. Tennessee Provectus Biopharmaceuticals Austra |
|
| March 28, 2025 |
Provectus Biopharmaceuticals, Inc. Securities Trading Policy Exhibit 19 Provectus BIOPharmaceuticals, Inc. SECURITIES TRADING POLICY The Board of Directors of Provectus Biopharmaceuticals, Inc. (the “Company”) has adopted the following Securities Trading Policy (the “Policy”) effective as of December 17, 2013. I. SUMMARY ● You may not trade in Company stock when you have material information about the Company that has not been publicly released. ● You may n |
|
| March 28, 2025 |
Exhibit 4.7 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Provectus Biopharmaceuticals, Inc. (the “Company,” “Provectus,” “we” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Common Stock. Description of Common Stock The following description of our Common Stock is a summary a |
|
| January 22, 2025 |
Exhibit 10.1 FINANCING TERM SHEET BY PROVECTUS BIOPHARMACEUTICALS, INC. DATED EFFECTIVE: January 15, 2025 The following is a summary of the terms and conditions of a proposed financing plan (the “Plan”) developed by Provectus Biopharmaceuticals, Inc. (the “Company”). The Plan was approved by the Board of Directors of the Company (the “Board”) on January 15, 2025. Total Financing Commitment This Fi |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Empl |
|
| January 22, 2025 |
Exhibit 4.1 THIS UNSECURED CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED AND QUALIFIED PURSUANT TO THE APPLICABLE PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION AND QUALIFICATION AP |
|
| December 26, 2024 |
Exhibit 10.1 Assignment and Assumption Agreement This Assignment and Assumption Agreement (this “Assignment Agreement”), effective as of December 9, 2024 (the “Effective Date”), is by and between Provectus Biopharmaceuticals, Inc., a Delaware Corporation, having business offices at 800 S. Gay Street, Suite 1610, Knoxville TN 37929 (“Assignor”), and VisiRose, Inc., a Delaware Corporation, having bu |
|
| December 26, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emp |
|
| December 11, 2024 |
Exhibit 99.2 Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology KNOXVILLE, Tenn., December 11, 2024 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”), Provectus’s first Founded Entity. This n |
|
| December 11, 2024 |
Exhibit 99.1 VisiRose Introduces Revolutionary Therapy for Severe Eye Infections Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, Tenn. — December 10, 2024 — VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious ke |
|
| December 11, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Empl |
|
| December 6, 2024 |
PVCT / Provectus Biopharmaceuticals, Inc. / Pershing Edward Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74373P108 (CUSIP Number) Heather Raines 800 S. Gay Street, Suite 1610 Knoxville, TN 37929 (866) 594-59 |
|
| December 5, 2024 |
Exhibit 10.1 COMMON SHARE STOCK OPTION AGREEMENT THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. PROVE |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Empl |
|
| December 5, 2024 |
Exhibit 10.2 COMMON SHARE STOCK OPTION AGREEMENT (NON-VESTING) THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT R |
|
| December 5, 2024 |
Exhibit 10.3 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of this 1st day of December 2024 by and between PROVECTUS BIOPHARMACEUTICALS, INC., a Delaware Corporation with its principal place of business in Knoxville, Tennessee (the “Company”), and Heather Raines (the “Executive”). WITNESSETH: WHEREAS, the Company recognizes the value of the Executive’s background, experience, and c |
|
| November 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emp |
|
| November 14, 2024 |
Fourth Quarter 2024 Investor Update presentation slides Exhibit 99.1 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVEC |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2024 |
PVCT / Provectus Biopharmaceuticals, Inc. / Morris Jeffrey Allen Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74373P108 (CUSIP Number) Jeffrey Allen Morris 1729 Triangle Park Dr. Maryville, TN 37801 (865) 981-8822 (Nam |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS B |
|
| July 17, 2024 |
Exhibit 4.1 THIS UNSECURED CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED AND QUALIFIED PURSUANT TO THE APPLICABLE PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION AND QUALIFICATION AP |
|
| July 17, 2024 |
Exhibit 10.1 FINANCING TERM SHEET BY PROVECTUS BIOPHARMACEUTICALS, INC. DATED EFFECTIVE: July 18, 2024 The following is a summary of the terms and conditions of a proposed financing plan (the “Plan”) developed by Provectus Biopharmaceuticals, Inc. (the “Company”). The Plan was approved by the Board of Directors of the Company (the “Board”) on July 18, 2024. Total Financing Commitment This Financin |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| July 3, 2024 |
PVCT / Provectus Biopharmaceuticals, Inc. / Pershing Edward Activist Investment SC 13D 1 formsc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74373P108 (CUSIP Number) Heather Raines 800 S. Gay Street, Suite 1610 Knoxville, TN 37929 (866) 594-5999 (Nam |
|
| June 25, 2024 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D-1 CONVERTIBLE PREFERRED STOCK OF PROVECTUS BIOPHARMACEUTICALS, INC. PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW Provectus Biopharmaceuticals, Inc. (the “Company”), a corporation organized and existing and by virtue of the General Corporation Law of the State of |
|
| June 25, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK OF PROVECTUS BIOPHARMACEUTICALS, INC. PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW Provectus Biopharmaceuticals, Inc. (the “Company”), a corporation organized and existing and by virtue of the General Corporation Law of the State of De |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (Commi |
|
| June 25, 2024 |
Exhibit 10.1 CONVERSION AGREEMENT THIS CONVERSION AGREEMENT (this “Agreement”) is entered into as of June 21, 2024 (the “Agreement Date”) by and between Provectus Biopharmaceuticals, Inc., a Delaware corporation (“Provectus”), and Dominic Rodrigues, an individual stockholder, director and officer of Provectus (the “Stockholder”). Provectus and the Stockholder are collectively referred to herein as |
|
| June 21, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additiona |
|
| June 20, 2024 |
2024 Annual Meeting of Stockholders presentation slides Exhibit 99.1 |
|
| June 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additiona |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additiona |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36457 PROVECTUS BIOPHARMACEUTICALS, IN |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additiona |
|
| April 16, 2024 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of this 16th day of April 2024 by and between PROVECTUS BIOPHARMACEUTICALS, INC., a Delaware Corporation with its principal place of business in Knoxville, Tennessee (the “Company”), and Edward Pershing (the “Executive”). WITNESSETH: WHEREAS, the Company recognizes the value of the Executive’s background and experience, and desires |
|
| April 16, 2024 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of this 16th day of April 2024 by and between PROVECTUS BIOPHARMACEUTICALS, INC., a Delaware Corporation with its principal place of business in Knoxville, Tennessee (the “Company”), and Dominic Rodrigues (the “Executive”). WITNESSETH: WHEREAS, the Company recognizes the value of the Executive’s background and experience, and desir |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (Comm |
|
| April 16, 2024 |
Exhibit 99.1 Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation ● Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced additions to its executive leadership team, |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS BIOPHARMACEUTICALS, |
|
| March 28, 2024 |
Exhibit 4.5 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Provectus Biopharmaceuticals, Inc. (the “Company,” “Provectus,” “we” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Common Stock. Description of Common Stock The following description of our Common Stock is a summary a |
|
| March 27, 2024 |
Exhibit 99.1 Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium ● New Provectus Spinout Company Would Commercialize Combination Therapy of University’s Light Source Medical Device and Provectus’s Pharmaceutical-Grade Rose Bengal Sodium KNOXVILLE, TN, March |
|
| March 27, 2024 |
Exhibit 10.1 CONFIDENTIAL UNIVERSITY OF MIAMI EXCLUSIVE LICENSE AGREEMENT (WITH EQUITY) This Exclusive License Agreement (with Equity) (this “Agreement”) is entered into and made effective as of the last dated signature below (the “Effective Date”) between UNIVERSITY OF MIAMI, a Florida not- for-profit corporation, having business offices at 1951 NW 7th Avenue, Suite 300, Miami, Florida 33136 (“UN |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (Comm |
|
| March 26, 2024 |
Exhibit 10.1 INDEPENDENT CONTRACTOR AND DIRECTOR FEE TERMINATION AGREEMENT AND RELEASE This Independent Contractor and Director Fee Termination Agreement and Release (“Agreement”) is made and entered into as of March 25, 2024 (the “Effective Date”) by and between Bruce Horowitz, a California citizen (“Contractor”), and Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”) (col |
|
| March 26, 2024 |
Independent Contractor Agreement, dated March 25, 2024, between the Company and Dominic Rodrigues. Exhibit 10.2 INDEPENDENT CONTRACTOR AGREEMENT THIS AGREEMENT is made and entered by and between PROVECTUS BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and DOMINIC RODRIGUES (the “Contractor”). Collectively the Company and the Contractor shall be referred to herein as “the Parties.” WHEREAS, the Company is a clinical-stage biotechnology company developing immunotherapy medicines |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (Comm |
|
| February 22, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (C |
|
| February 22, 2024 |
Investor Presentation, dated February 22, 2024 Exhibit 99.1 |
|
| February 15, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (C |
|
| February 15, 2024 |
Exhibit 99.1 Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call KNOXVILLE, TN, February 15, 2024 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will host a conference call starting at 3 p.m. EST on Thursday, February 22, 2024, to provide Company updates. The conference call may be accessed by registe |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVEC |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS B |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 21, 2023 |
2023 Annual Meeting of Stockholders presentation slides Exhibit 99.1 |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additiona |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS |
|
| May 9, 2023 |
PVCT / Provectus Biopharmaceuticals Inc / Morris Jeffrey Allen Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74373PB99 (CUSIP Number) Jeffrey Allen Morris 1729 Triangle Park Dr. Maryville, TN 37801 (865) 981-8822 (Name, address and telephon |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employ |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS BIOPHARMACEUTICALS, |
|
| March 30, 2023 |
Exhibit 4.5 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Provectus Biopharmaceuticals, Inc. (the “Company,” “Provectus”, “we” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Common Stock. Description of Common Stock The following description of our Common Stock is a summary a |
|
| March 28, 2023 |
PVCT / Provectus Biopharmaceuticals Inc / Morris Jeffrey Allen Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74373PB99 (CUSIP Number) Jeffrey Allen Morris 1729 Triangle Park Dr. Maryville, TN 37801 (865) 981-8822 (Name, address and telephon |
|
| January 9, 2023 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Provectus Biopharmaceuticals Releases 2023 Stockholder Letter KNOXVILLE, TN, January 9, 2023 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that it had issued a beginning-of-the-year letter for 2023 to the Company’s stockholders, which may be found below. 2023 Letter to Stockholders Dear Provectus Stockholders, Thank you for your continued support of P |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emplo |
|
| December 12, 2022 |
Exhibit 99.1 Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023 KNOXVILLE, TN, December 12, 2022 (GLOBE NEWSWIRE) ? Provectus (OTCQB: PVCT) today announced that the Company?s Board of Directors (Board) has decided to not undertake the reverse stock split and authorize |
|
| December 12, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emp |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVEC |
|
| November 9, 2022 |
Exhibit 10.1 FINANCING TERM SHEET BY PROVECTUS BIOPHARMACEUTICALS, INC. DATED EFFECTIVE: September 20, 2022 The following is a summary of the terms and conditions of a proposed financing plan (the “Plan”) developed by Provectus Biopharmaceuticals, Inc. (the “Company”). The Plan was approved by the Board of Directors of the Company (the “Board”) on September 20, 2022. Total Financing Commitment Thi |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Em |
|
| September 26, 2022 |
Exhibit 4.1 THIS UNSECURED CONVERTIBLE PROMISSORY NOTE (THIS ?NOTE?) HAS NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED AND QUALIFIED PURSUANT TO THE APPLICABLE PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION AND QUALIFICATION AP |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS B |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additiona |
|
| June 22, 2022 |
2022 Annual Meeting of Stockholders presentation slides Exhibit 99.1 |
|
| June 22, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additiona |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additiona |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additiona |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS |
|
| May 12, 2022 |
Exhibit 3.4 provectus BIOpharmaceuticals, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D-1 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW (As Amended by Certificate of Amendment, dated March 30, 2022) Pursuant to Section 151 of the General Corporation Law of the State of Delaware, PROVECTUS BIOPHARMACEUTICALS, INC., a |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional |
|
| April 29, 2022 |
the Company’s definitive proxy statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additiona |
|
| April 19, 2022 |
Exhibit 99.1 Provectus Biopharmaceuticals Seeks Stockholder Approval at 2022 Annual Meeting for Authority to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio KNOXVILLE, TN, April 19, 2022 (GLOBE NEWSWIRE) ? Provectus (OTCQB: PVCT) today announced that, in conjunction with the filing of the Company?s preliminary 2022 proxy statement (Pre-14A), P |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additiona |
|
| April 19, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employ |
|
| April 5, 2022 |
Certificate of Elimination with respect to Series B Convertible Preferred Stock. Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF ELIMINATION OF CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE PREFERRED STOCK OF PROVECTUS BIOPHARMACEUTICALS, INC. 1. The name of the Corporation is Provectus Biopharmaceuticals, Inc. (the ?Company?). 2. The Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock of the Company (the ?Series B Prefer |
|
| April 5, 2022 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D-1 CONVERTIBLE PREFERRED STOCK OF PROVECTUS BIOPHARMACEUTICALS, INC. PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW Provectus Biopharmaceuticals, Inc. (the ?Company?), a corporation organized and existing and by virtue of the General Corporation Law of the State of |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employ |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS BIOPHARMACEUTICALS, |
|
| March 29, 2022 |
Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Provectus Biopharmaceuticals, Inc. (the ?Company,? ?Provectus?, ?we? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our Common Stock. Description of Common Stock The following description of our Common Stock is a summary a |
|
| November 10, 2021 |
Exhibit 10.1 FINANCING TERM SHEET BY PROVECTUS BIOPHARMACEUTICALS, INC. DATED EFFECTIVE: August 13, 2021 The following is a summary of the terms and conditions of a proposed financing plan (the ?Plan?) developed by Provectus Biopharmaceuticals, Inc. (the ?Company?). The Plan was approved by the Board of Directors of the Company (the ?Board?) on August 13, 2021. Total Financing Commitment This Fina |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVEC |
|
| September 7, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emplo |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emplo |
|
| August 18, 2021 |
Exhibit 4.1 THIS UNSECURED CONVERTIBLE PROMISSORY NOTE (THIS ?NOTE?) HAS NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED AND QUALIFIED PURSUANT TO THE APPLICABLE PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION AND QUALIFICATION AP |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS B |
|
| June 30, 2021 |
PVCT / Provectus Biopharmaceuticals Inc / WACHTER ERIC PHD Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74373P108 (CUSIP Number) Eric Wachter 10025 Investment Drive, Suite 250 Knoxville, TN 37932 (866) 594-5999 (Name, Address and Teleph |
|
| June 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 24, 2021 |
Exhibit 3.1 provectus BIOpharmaceuticals, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW Pursuant to Section 151 of the General Corporation Law of the State of Delaware, PROVECTUS BIOPHARMACEUTICALS, INC., a corporation organized and existing under the General Corporation |
|
| June 24, 2021 |
Exhibit 3.2 provectus BIOpharmaceuticals, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D-1 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW Pursuant to Section 151 of the General Corporation Law of the State of Delaware, PROVECTUS BIOPHARMACEUTICALS, INC., a corporation organized and existing under the General Corporati |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 23, 2021 |
2021 Annual Meeting of Stockholders presentation slides Exhibit 99.1 |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVEC |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [X] Definiti |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definiti |
|
| March 2, 2021 |
Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Provectus Biopharmaceuticals, Inc. (?Provectus?, ?we? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our Common Stock. Description of Common Stock The following description of our Common Stock is a summary and does not pur |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS BIOPHARMACEUTIC |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PR |
|
| August 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECT |
|
| July 16, 2020 |
Exhibit 99.1 Provectus Biopharmaceuticals Announces Change to Board of Directors KNOXVILLE, TN, July 16, 2020 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today is pleased to announce the addition of Webster Bailey to the Company’s Board of Directors (the “Board”), effective as of July 20, 2020. Mr. Bailey is a member of the board of directors of the Clover Fork Coal Company investment trust (the “C |
|
| July 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2020 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| July 16, 2020 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of July 20, 2020, between PROVECTUS Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Webster Bailey (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided wit |
|
| June 25, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 24, 2020 |
2020 Annual Meeting of Stockholders presentation slides Exhibit 99.1 |
|
| June 24, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVEC |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [X] Definiti |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definiti |
|
| March 5, 2020 |
Exhibit 4.10 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Provectus Biopharmaceuticals, Inc. (“Provectus”, “we” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Common Stock. Description of Common Stock The following description of our Common Stock is a summary and does not pu |
|
| March 5, 2020 |
Exhibit 10.39 2020 FINANCING TERM SHEET The following is a summary of the terms and conditions of the financing plan (the “Plan”) developed by Provectus Biopharmaceuticals, Inc. (the “Company”). The Plan was approved by the Board of Directors of the Company (the “Board”) on December 31, 2019. The 2020 Term Sheet is similar to the Definitive Financing Commitment Term Sheet entered into between the |
|
| March 5, 2020 |
PVCT / Provectus Biopharmaceuticals, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS BIOPHARMACEUTIC |
|
| January 7, 2020 |
Exhibit 4.1 prh 2 SECURED Convertible Promissory NOTE (this “Note”) $[●] [●], [●], 2020 FOR VALUE RECEIVED, the undersigned Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Borrower”), hereby promises to pay to the order of [●] at the Lender’s address located at [●] or at such other place as the Lender may designate to the Borrower in writing from time to time, the principal sum se |
|
| January 7, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2019 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emp |
|
| December 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2019 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emp |
|
| November 12, 2019 |
PVCT / Provectus Biopharmaceuticals, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PR |
|
| August 8, 2019 |
PVCT / Provectus Biopharmaceuticals, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECT |
|
| June 27, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2019 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| May 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2019 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employer |
|
| May 20, 2019 |
EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of this 17th day of May 2019 by and between PROVECTUS BIOPHARMACEUTICALS, INC. |
|
| May 14, 2019 |
PVCT / Provectus Biopharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [X] Definiti |
|
| May 14, 2019 |
PVCT / Provectus Biopharmaceuticals, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definiti |
|
| May 13, 2019 |
PVCT / Provectus Biopharmaceuticals, Inc. 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVEC |
|
| May 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2019 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employer |
|
| May 9, 2019 |
AMENDMENT NO. 2 TO THE INDEPENDENT CONTRACTOR AGREEMENT THIS AMENDMENT NO. 2 to the Independent Contractor Agreement (the “Agreement”) is effective as of May 8, 2019 and is by and between PROVECTUS BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and BRUCE HOROWITZ, a California citizen (the “Contractor”). Collectively the Company and the Contractor shall be referred to herein as “ |
|
| May 9, 2019 |
PVCT / Provectus Biopharmaceuticals, Inc. 10-K/A Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36457 PROVECTUS BIOPHARMACEUTICALS |
|
| May 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2019 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employ |
|
| March 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2019 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employ |
|
| March 25, 2019 |
EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of this 25th day of March 2019 by and between PROVECTUS BIOPHARMACEUTICALS, INC. |
|
| March 7, 2019 |
PVCT / Provectus Biopharmaceuticals, Inc. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36457 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registran |
|
| January 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2019 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Empl |
|
| November 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emp |
|
| November 8, 2018 |
PVCT / Provectus Biopharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PR |
|
| August 7, 2018 |
PVCT / Provectus Biopharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECT |
|
| July 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| July 30, 2018 |
EX-10.1 2 ex10-1.htm SECURED Convertible Promissory NOTE (this “Note”) $200,000 July 26, 2018 FOR VALUE RECEIVED, the undersigned Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Borrower”), hereby promises to pay to the order of Edward V. Pershing at the Lender’s office located at 2220 Sutherland Avenue, Knoxville, TN 37919 or at such other place as the Lender may designate to the |
|
| July 2, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emp |
|
| June 27, 2018 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commi |
|
| May 9, 2018 | ||
| May 9, 2018 | ||
| May 9, 2018 | ||
| May 9, 2018 | ||
| May 9, 2018 |
PVCT / Provectus Biopharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS BIOPHARMAC |
|
| April 30, 2018 |
PVCT / Provectus Biopharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [X] Definitive Additional Materials [ ] Soliciting Material under §240.14a-12 Provectus |
|
| April 30, 2018 |
PVCT / Provectus Biopharmaceuticals, Inc. DEF 14A DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material un |
|
| April 24, 2018 |
Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of April 19, 2018, between PROVECTUS Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and John W. “Jack” Lacey, III, MD (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they |
|
| April 24, 2018 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of April 19, 2018, between PROVECTUS Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Ed Pershing (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with |
|
| April 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employ |
|
| April 24, 2018 |
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS Contact: Provectus Biopharmaceuticals, Inc. Tim Scott, Ph.D. President Phone: (866) 594-5999 FOR IMMEDIATE RELEASE PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS ● Ed Pershing, CPA elected new Board chair ● Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 — Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, |
|
| April 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| March 22, 2018 |
the Company’s Form 10-K for the year ended December 31, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36457 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registran |
|
| February 26, 2018 |
Note identifier PRH81 SECURED Convertible Promissory NOTE (this ?Note?) $250,000 February 23, 2018 FOR VALUE RECEIVED, the undersigned Provectus Biopharmaceuticals, Inc. |
|
| February 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (C |
|
| February 22, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emp |
|
| February 22, 2018 |
provectus biopharmaceuticals provides update on GI Cancer program for INVESTIGATIONAL DRUG PV-10 Contact: Provectus Biomaceuticals, Inc. Tim Scott, Ph.D. President Phone: (866) 594-5999 FOR IMMEDIATE RELEASE provectus biopharmaceuticals provides update on GI Cancer program for INVESTIGATIONAL DRUG PV-10 ? Current Phase 1 basket study continues to enroll and treat patients for HCC and liver cancer metastases (colorectal, lung, pancreatic, melanoma, ovarian, and breast); updated data presentati |
|
| January 30, 2018 |
EX-10.1 2 ex10-1.htm Note identifier PRH1 – Second note issued SECURED Convertible Promissory NOTE (this “Note”) $500,000 January 25, 2018 FOR VALUE RECEIVED, the undersigned Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Borrower”), hereby promises to pay to the order of Eric A. Wachter, a resident of the State of Tennessee (the “Lender”), at the Lender’s address 138 Baypath Dri |
|
| January 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Empl |
|
| December 12, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Emp |
|
| December 12, 2017 |
Contact: Provectus Biopharmaceuticals, Inc. Tim Scott, Ph.D. President FOR IMMEDIATE RELEASE Phone: (866) 594-5999 PROVECTus Announces resolutIon of SEC investigation ? SEC ?takes into account the proactive remediation and cooperation by the [C]ompany?s new leadership? ? ? No monetary penalties; Commission notes actions already taken by Provectus to remedy internal controls ? KNOXVILLE, TN, Decemb |
|
| November 30, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (C |
|
| November 30, 2017 |
Contact: Provectus Biopharmaceuticals, Inc. Tim Scott, PhD President FOR IMMEDIATE RELEASE Phone: (866) 594-5999 PROVECTus Announces Results from mechanism of action study of topical PH-10 for the Treatment of PSORIASIS ? Responses mediated by multiple pathways, including IL-17, IL-22 and interferons ? ? Down-regulation of more than 500 disease-related genes; wide range of central ?psoriasis-relat |
|
| November 8, 2017 |
PVCT / Provectus Biopharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS BIOPHA |
|
| October 18, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Empl |
|
| October 18, 2017 |
Contact: Provectus Biopharmaceuticals, Inc. Tim Scott, Ph.D. President Phone: 866-594-5999 FOR IMMEDIATE RELEASE PROVECTus Announces preliminary Results from Phase 1b Trial of intralesional pv-10 in Combination with KEYTRUDA? (pembrolizumab) for the Treatment of stage IV Melanoma ? Adverse events consistent with established patterns for each drug; no unexpected toxicities observed ? ? 50% overall |
|
| September 21, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Em |
|
| September 21, 2017 |
September 21, 2017 Dear Provectus Shareholders, Thank you for your continued support of the Company. |
|
| August 9, 2017 |
AMENDMENT NO. 1 TO THE INDEPENDENT CONTRACTOR AGREEMENT THIS AMENDMENT NO. 1 to the Independent Contractor Agreement (the “Agreement”) is effective as of May 9, 2017 and is by and between PROVECTUS BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and BRUCE HOROWITZ, a California citizen (the “Contractor”). Collectively the Company and the Contractor shall be referred to herein as “ |
|
| August 9, 2017 |
the Company’s Form 10-Q for the quarter ended June 30, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVECTUS BIOPHARMACE |
|
| August 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employe |
|
| June 1, 2017 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (Co |
|
| May 10, 2017 |
EX-10.2 Exhibit 10.2 CONFIDENTIAL AMENDED AND RESTATED DEFINITIVE FINANCING COMMITMENT TERM SHEET TO PROVECTUS BIOPHARMACEUTICALS, INC. DATED EFFECTIVE: March 19, 2017 The following is a summary of the terms and conditions of a proposed financing plan (the ?Plan?) offered by certain individuals to Provectus Biopharmaceuticals, Inc. (the ?Company?). The Plan supersedes the proposal to the Board of |
|
| May 10, 2017 |
Provectus Biopharmaceuticals FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36457 PROVEC |
|
| April 27, 2017 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporati |
|
| April 27, 2017 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 21, 2017 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ? Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary proxy statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive proxy statement ? Definitive additional materials ? Soliciting material pursuant to ?240. |
|
| April 21, 2017 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE MKT LLC (the 'Exchange' ) hereby notifies the Securities and Exchange Commission ('SEC') of its intention to remove the entire class of common stock (the 'Common Stock') and warrants exercisable for shares of Common Stock with an exercise price of $0. |
|
| April 21, 2017 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE MKT LLC (the 'Exchange' ) hereby notifies the Securities and Exchange Commission ('SEC') of its intention to remove the entire class of common stock (the 'Common Stock') and warrants exercisable for shares of Common Stock with an exercise price of $0. |
|
| April 20, 2017 |
Provectus Biopharmaceuticals PRER14A PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 20, 2017 |
8-K 1 d379414d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisd |
|
| April 20, 2017 |
EX-99.1 Exhibit 99.1 Contact: Provectus Biopharmaceuticals, Inc. Timothy C. Scott, President Phone: 866-594-5999 Allison + Partners Tom Smith, Managing Director ? Investor Relations Phone: 646-428-0653 FOR IMMEDIATE RELEASE PROVECTUS BIOPHARMACEUTICALS REESTABLISHES STRATEGIC ADVISORY BOARD Ed Pershing Named Strategic Advisory Board Chairman, Also Appointed Board of Directors Observer; Bruce Horow |
|
| April 20, 2017 |
EX-10.1 Exhibit 10.1 INDEPENDENT CONTRACTOR AGREEMENT THIS AGREEMENT is made and entered by and between PROVECTUS BIOPHARMACEUTICALS, INC., a Delaware corporation (the ?Company?) and BRUCE HOROWITZ, a California citizen (the ?Contractor?). Collectively the Company and the Contractor shall be referred to herein as ?the Parties.? WHEREAS, the Company is a development-stage biopharmaceutical company |
|
| April 19, 2017 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ? Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary proxy statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive proxy statement ? Definitive additional materials ? Soliciting material pursuant to ?240. |
|
| April 18, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporati |
|
| April 17, 2017 |
Provectus Biopharmaceuticals PRE 14A PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 17, 2017 |
PVCT / Provectus Biopharmaceuticals, Inc. / MILLER COURTLANDT G - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74373F100 (CUSIP Number) Courtlandt G. Miller 251 Royal Palm Way, Suite 205 Palm Beach, FL 33480 (561) 543-6802 with cop |
|
| April 4, 2017 |
EX-10.3 Exhibit 10.3 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the Agreement) is made and entered into as of April 3, 2017, between PROVECTUS Biopharmaceuticals, Inc., a Delaware corporation (the Company), and Dominic Rodrigues (Indemnitee). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are p |
|
| April 4, 2017 |
EX-10.2 Exhibit 10.2 AMENDED AND RESTATED SECURED CONVERTIBLE PROMISSORY NOTE (this ?Note?) $2,500,000 April 3, 2017 FOR VALUE RECEIVED, the undersigned Provectus Biopharmaceuticals, Inc., a Delaware corporation (the ?Borrower?), hereby promises to pay to the order of Eric A. Wachter, a resident of the State of Tennessee (the ?Lender?), at the Lender?s office located at 7327 Oak Ridge Highway, Sui |
|
| April 4, 2017 |
EX-10.4 Exhibit 10.4 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of April 3, 2017, between PROVECTUS Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Bruce Horowitz (?Indemnitee?). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are prov |
|
| April 4, 2017 |
8-K 1 d356774d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction |
|
| April 4, 2017 |
Exhibit 99.1 Contact: Provectus Biopharmaceuticals, Inc. Timothy C. Scott, President Phone: 866-594-5999 Allison + Partners Tom Smith, Managing Director Investor Relations Phone: 646-428-0653 FOR IMMEDIATE RELEASE PROVECTUS BIOPHARMACEUTICALS CLOSES DEFINITIVE FINANCING WITH PRH GROUP Dominic Rodrigues Elected New Chairman, Bruce Horowitz Named New Director KNOXVILLE, TN, April 4, 2017 Provect |
|
| April 4, 2017 |
EX-10.1 Exhibit 10.1 SECURED CONVERTIBLE PROMISSORY NOTE (this ?Note?) Up to $2,500,000 April 3, 2017 FOR VALUE RECEIVED, the undersigned Provectus Biopharmaceuticals, Inc., a Delaware corporation (the ?Borrower?), hereby promises to pay to the order of Cal Enterprises LLC, a Nevada limited liability company (the ?Lender?), at the Lender?s office located at 1930 Village Center Circle, #3-206, Las |
|
| March 31, 2017 |
Provectus Biopharmaceuticals FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 31, 2017 |
EX-3.1 Exhibit 3.1 STATE of DELAWARE CERTIFICATE of INCORPORATION A STOCK CORPORATION (As amended through November 28, 2016) ARTICLE I NAME The name of the Corporation is Provectus Biopharmaceuticals, Inc. ARTICLE II REGISTERED AGENT Its registered office in the State of Delaware is to be located at 160 Greentree Drive, Suite 101, in the City of Dover, County of Kent, Zip Code 19904. The registere |
|
| March 31, 2017 |
Exhibit 10.18 AMENDMENT NO. 1 TO THE INDEPENDENT CONTRACTOR AGREEMENT THIS AMENDMENT NO. 1 to the Independent Contractor Agreement (the ?Agreement?) is effective as of December 3, 2016 and is by and between PROVECTUS BIOPHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and JOHN R. GLASS, an Illinois citizen (?Contractor?). Collectively the Company and the Contractor shall be referred |
|
| March 31, 2017 |
Exhibit 21 SUBSIDIARIES OF PROVECTUS BIOPHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation Xantech Pharmaceuticals, Inc. Tennessee Pure-ific Corporation Nevada Provectus Biotech, Inc. Tennessee Provectus Devicetech, Inc. Tennessee Provectus Imaging, Inc. Tennessee IP Tech, Inc. Tennessee Provectus Pharmatech, Inc. Provectus Biopharmaceuticals Australia PTY LTD Tennessee New South Wales |
|
| March 30, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Em |
|
| March 30, 2017 |
PVCT / Provectus Biopharmaceuticals, Inc. / CULPEPPER PETER R - FORM SC 13D/A Activist Investment Form SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74373F100 (CUSIP Number) with copies to: Peter R. Culpepper P.O. Box 32429 Knoxville, TN 37930 (865) 604-0657 David |
|
| March 30, 2017 |
EX-1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons who executes a copy of this Joint Filing Agreement agrees to the joint filing on behalf of each of them of a Statement on Schedule 13D relating to securities of Provectus Biopharmaceuticals, Inc. |
|
| March 30, 2017 |
EX-2 Exhibit 2 AMENDED INVESTMENT AGREEMENT This is an amended and restated agreement (this “Amended Agreement”) among each of the persons (each an “Investor,” and together the “Investors”) who signs a signature page to this Amended Agreement (a “Signature Page”) regarding the terms on which each of the Investors agrees that, upon fulfillment of certain conditions, it will purchase Units consisting of Series D Preferred Stock (“Series D Stock”) and common stock (“Common Stock”) of Provectus Biopharmaceuticals, Inc. |
|
| March 30, 2017 |
PVCT / Provectus Biopharmaceuticals, Inc. / MILLER COURTLANDT G - SC 13D Activist Investment SC 13D 1 d370149dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74373F100 (CUSIP Number) Courtlandt G. Miller 251 Royal Palm Way, Suite 205 Palm Beach, FL 33480 (561) 543-6802 wit |
|
| March 23, 2017 |
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES TERMS OF DEFINITIVE FINANCING COMMITMENT EX-99.1 Exhibit 99.1 Contact: Allison + Partners Provectus Biopharmaceuticals, Inc. Tom Smith, Managing Director ? Timothy C. Scott, President Investor Relations Phone: 866-594-5999 Phone: 646-428-0653 FOR IMMEDIATE RELEASE PROVECTUS BIOPHARMACEUTICALS ANNOUNCES TERMS OF DEFINITIVE FINANCING COMMITMENT KNOXVILLE, TN, March 23, 2017 ? Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbi |
|
| March 23, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (I |
|
| March 21, 2017 |
EX-99.3 Exhibit 3 Purchase Proposal Summary The following summary describes the principal terms of a proposed offer to Provectus Biopharmaceuticals, Inc. (the “Company”) by a group of investors (the “Investors”) to purchase the securities of the Company described below. Securities to be purchased from the Company A minimum of 80 and a maximum of 200 units (“Units”), each Unit consisting of one sha |
|
| March 21, 2017 |
EX-99.4 EXHIBIT 4 Courtlandt G. Miller Dear Mr. Smith, I was disappointed that instead of returning my phone call two weeks ago, you requested, through your counsel, that I communicate only with her. As Chairman of the Board, I had hoped that, lawyers aside, we could have an open and honest discussion of the direction of Provectus and what your current plans were compared to ours. The past is the |
|
| March 21, 2017 |
PVCT / Provectus Biopharmaceuticals, Inc. / CULPEPPER PETER R - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74373F100 (CUSIP Number) Peter R. Culpepper P.O. Box 32429 Knoxville, TN 37930 (865) 604-0657 (Name, Address and Telepho |
|
| March 20, 2017 |
EX-99.1 Exhibit 99.1 Contact: Provectus Biopharmaceuticals, Inc. Timothy C. Scott, President Phone: 866-594-5999 Allison + Partners Tom Smith, Managing Director ? Investor Relations Phone: 646-428-0653 FOR IMMEDIATE RELEASE PROVECTUS BIOPHARMACEUTICALS ENTERS INTO DEFINITIVE FINANCING COMMITMENT TERM SHEET Terminates Previously Announced Rights Offering KNOXVILLE, TN, March 20, 2017 ? Provectus Bi |
|
| March 20, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d357971d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisd |
|
| March 16, 2017 |
Provectus Biopharmaceuticals NT 10-K NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 001-36457 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition |
|
| March 6, 2017 |
424B3 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated January 30, 2017) Filed pursuant to Rule 424(b)(3) Registration No. 333-213986 Subscription Rights to Purchase Up to 19,662,782 Units Consisting of an Aggregate of Up to 78,651,128 Shares of Common Stock and Up to 9,831,391 Shares of Series C Convertible Preferred Stock at a Subscription Price of $1.00 Per Unit This Prospectus Supplement No. 3 |
|
| March 6, 2017 |
EX-99.1 Exhibit 99.1 Contact: Allison + Partners Provectus Biopharmaceuticals, Inc. Tom Smith, Managing Director Timothy C. Scott, President Investor Relations Phone: 866-594-5999 Phone: 646-428-0653 FOR IMMEDIATE RELEASE PROVECTUS BIOPHARMACEUTICALS, INC. ANNOUNCES EXTENSION OF RIGHTS OFFERING DUE TO RECEIPT OF UNSOLICITED INVESTMENT PROPOSALS TO INVEST IN PROVECTUS KNOXVILLE, TN, March 6, 2017 |
|
| March 6, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (Commi |
|
| February 24, 2017 |
EX-99.1 Exhibit 99.1 Contact: Provectus Biopharmaceuticals, Inc. Timothy C. Scott, President Phone: 866-594-5999 Allison + Partners Tom Smith, Managing Director ? Investor Relations Phone: 646-428-0653 FOR IMMEDIATE RELEASE PROVECTUS BIOPHARMACEUTICALS PROVIDES INFORMATION ON RIGHTS OFFERING DEADLINE Subscription Period Ends On March 3 But Some Brokers Or Banks May Set Earlier Deadlines to Allow f |
|
| February 24, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission |
|
| February 23, 2017 |
Exhibit 99.1 Contact: Allison + Partners Provectus Biopharmaceuticals, Inc. Tom Smith, Managing Director Timothy C. Scott, President Investor Relations Phone: 866-594-5999 Phone: 646-428-0653 FOR IMMEDIATE RELEASE PROVECTUS BIOPHARMACEUTICALS APPOINTS BRUCE HOROWITZ AND DOMINIC RODRIGUES AS SPECIAL ADVISERS TO THE BOARD OF DIRECTORS Eric Wachter, Ph.D., Co-Founder and Chief Technology Officer, M |
|
| February 23, 2017 |
Provectus Biopharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation |
|
| February 21, 2017 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-213986 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated January 30, 2017) Subscription Rights to Purchase Up to 19,662,782 Units Consisting of an Aggregate of Up to 78,651,128 Shares of Common Stock and Up to 9,831,391 Shares of Series C Convertible Preferred Stock at a Subscription Price of $1.00 Per Unit This Prospectus Supplement No. 2 (?Sup |
|
| February 21, 2017 |
EX-10.1 Exhibit 10.1 CONVERTIBLE PROMISSORY NOTE (this ?Note?) Up to $2,500,000 February 21, 2017 FOR VALUE RECEIVED, the undersigned Provectus Biopharmaceuticals, Inc., a Delaware corporation (the ?Borrower?), hereby promises to pay to the order of Eric A. Wachter, Ph.D. a resident of the State of Tennessee (?Lender?), at Lender?s office located at 7327 Oak Ridge Highway, Suite A, Knoxville, Tenn |
|
| February 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (C |
|
| February 14, 2017 |
Provectus Biopharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation |
